[China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)

Announced Date: 2024-12-23 (December 23, 2024)

Asset Name: JYB1904 (RPT904)

Licensor (Seller): Shanghai Jemincare Pharmaceutical (China)

Licensee (Buyer): RAPT Therapeutics (US)

.

Asset Modality: monoclonal antibody (mAb)

Asset Target: anti-immunoglobulin E (IgE)

Potential Indication: several allergic disorders and allergic inflammatory diseases

Currently Stage <During The BD>: conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China

.

Scope of Authority:

RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan (together, the “Jemincare Territory”) to develop and commercialize RPT904. 

.

Payment Detail:

Jemincare  will receive:

Upfront payment $35 million,

Development, regulatory, and commercial milestones payment up to $672.5 million.

Royalties on future sales of RPT904 outside the Jemincare Territory. 

.

Link:

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody – RAPT Therapeutics

.

Note:

Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group 上海济煜医药，江西济民可信子公司